GENMAB AS SP.ADR/1/10DK 1 (GE91) - Cash Flow Conversion Efficiency

Latest as of December 2025: 0.051x

Based on the latest financial reports, GENMAB AS SP.ADR/1/10DK 1 (GE91) has a cash flow conversion efficiency ratio of 0.051x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€301.00 Million ≈ $351.90 Million USD) by net assets (€5.85 Billion ≈ $6.84 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See GE91 equity financing ratio to measure how much of total assets are equity-financed.

GENMAB AS SP.ADR/1/10DK 1 - Cash Flow Conversion Efficiency Trend (2021–2025)

This chart illustrates how GENMAB AS SP.ADR/1/10DK 1's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check GENMAB AS SP.ADR/1/10DK 1 cash flow quality index to evaluate the quality of earnings relative to operating cash generation.

GENMAB AS SP.ADR/1/10DK 1 Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of GENMAB AS SP.ADR/1/10DK 1 ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Rogers Communications Inc TO:RCI-B	0.060x
Tech Mahindra Limited NSE:TECHM	0.105x
Rentokil Initial PLC NYSE:RTO	0.091x
Woori Financial Group Inc KO:316140	0.118x
Banco de Chile F:G4RA	-0.033x
EchoStar Corporation NASDAQ:ECHO	0.042x
Sprott Physical Gold Trust TO:PHYS	-0.002x
YPF Sociedad Anonima NYSE:YPF	0.000x

Annual Cash Flow Conversion Efficiency for GENMAB AS SP.ADR/1/10DK 1 (2021–2025)

The table below shows the annual cash flow conversion efficiency of GENMAB AS SP.ADR/1/10DK 1 from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see GENMAB AS SP.ADR/1/10DK 1 market cap and net worth.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	€5.85 Billion ≈ $6.84 Billion	€1.19 Billion ≈ $1.39 Billion	0.203x	-4.21%
2024-12-31	€5.12 Billion ≈ $5.99 Billion	€1.08 Billion ≈ $1.27 Billion	0.212x	-9.30%
2023-12-31	€4.69 Billion ≈ $5.49 Billion	€1.10 Billion ≈ $1.28 Billion	0.233x	+62.82%
2022-12-31	€3.93 Billion ≈ $4.59 Billion	€563.05 Million ≈ $658.26 Million	0.143x	+42.85%
2021-12-31	€3.38 Billion ≈ $3.95 Billion	€339.18 Million ≈ $396.54 Million	0.100x	--

About GENMAB AS SP.ADR/1/10DK 1

F:GE91 Germany Biotechnology

Market Cap

$17.14 Billion

€14.66 Billion EUR

Market Cap Rank

#1624 Global

#351 in Germany

Share Price

€23.80

Change (1 day)

+3.48%

52-Week Range

€17.00 - €29.80

All Time High

€44.40